Patents by Inventor Amy H. Yin

Amy H. Yin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition comprising a cell expressing an AC133 cell surface antigen and an antibody or antigen-binding fragment
    Patent number: 8084033
    Abstract: Compositions comprising a cell expressing an AC133 cell surface antigen and an antibody, or antigen binding fragment thereof, that specifically binds to the antigen are provided. Expression of the antigen is highly tissue specific. It is detected on a subset of hematopoietic progenitor and stem cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: December 27, 2011
    Assignee: Amcell Corporation
    Inventors: Amy H. Yin, Sheri Miraglia, Wayne G. Godfrey, David W. Buck
  • Human Hematopoietic Stem And Progenitor Antigen And Methods For Its Use
    Publication number: 20090093052
    Abstract: A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
    Type: Application
    Filed: July 8, 2008
    Publication date: April 9, 2009
    Inventors: Amy H. Yin, Sheri Miraglia, David W. Buck
  • Human hematopoietic stem and progenitor cell antigen
    Patent number: 6455678
    Abstract: A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: September 24, 2002
    Assignee: AmCell Corporation
    Inventors: Amy H. Yin, Sheri Miraglia, Wayne G. Godfry, David W. Buck
  • Human hematopoietic stem and progenitor cell antigen and methods for its use
    Publication number: 20010051372
    Abstract: A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
    Type: Application
    Filed: June 13, 2001
    Publication date: December 13, 2001
    Inventors: Amy H. Yin, Sheri Miraglia, Wayne G. Godfrey, David W. Buck